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Abstract
Background: Without intervention, up to 25% of individuals chronically infected with hepatitis B virus (HBV) die of late
complications, including cirrhosis and liver cancer. The United States, which in 1991 implemented a strategy to eliminate HBV
transmission through universal immunization, is a country of low prevalence. Approximately 3,000–5,000 U.S.-acquired cases
of chronic hepatitis B have occurred annually since 2001. Many more chronically infected persons migrate to the United States
yearly from countries of higher prevalence. Although early identification of chronic HBV infection can reduce the likelihood of
transmission and late complications, immigrants are not routinely screened for HBV infection during or after immigration.
Methods: To estimate the number of imported cases of chronic hepatitis B, we multiplied country-specific prevalence
estimates by the yearly number of immigrants from each country during 1974–2008.
Results: During 1974–2008, 27.9 million immigrants entered the U.S. Sixty-three percent were born in countries of
intermediate or high chronic hepatitis B prevalence (range 2%–31%). On average, an estimated 53,800 chronic hepatitis B
cases were imported to the U.S. yearly from 2004 through 2008. The Philippines, China, and Vietnam contributed the most
imported cases (13.4%, 12.5%, and 11.0%, respectively). Imported cases increased from an estimated low of 105,750 during
the period 1974–1977 to a high of 268,800 in 2004–2008.
Conclusions: Imported chronic hepatitis B cases account for approximately 95% of new U.S. cases. Earlier case identification
and management of infected immigrants would strengthen the U.S. strategy to eliminate HBV transmission, and could delay
disease progression and prevent some deaths among new Americans.
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Introduction
Hepatitis B virus infection, which is transmitted via blood or
body fluids, is currently among the world’s top ten causes of
infectious disease-related mortality, resulting in over 500,000
deaths annually [1]. Acute infection with HBV is often
asymptomatic, and the risk of progression to chronic infection is
inversely related to age: approximately 90% of those infected
before 1 year of age will develop chronic infection, while far fewer
individuals infected after 5 years of age develop chronic infection
[2–3]. Individuals with chronic hepatitis B may be a major source
of HBV transmission, but are often unaware of their status [4].
Without intervention, approximately 25% of people with
chronic infections acquired before age 5 and 15% of those
acquiring infection at age 5 or after will die of late complications,
such as cirrhosis and hepatocellular carcinoma [4]. In fact, .50%
of all cases of hepatocellular carcinoma worldwide are associated
with HBV [5]. Early identification of infected patients allows for
the institution of medical monitoring and potentially therapy that
could delay or prevent late complications [4].
In 1991, the United States implemented a comprehensive
national strategy to eliminate HBV transmission through universal
immunization. Subsequently, the estimated incidence of new,
domestically acquired cases of chronic hepatitis B declined from
approximately 10 cases/100,000 population in 1991 to the current
rate of 1.2 cases/100,000 (CDC, unpublished data). The United
States also has a low (,0.3%) prevalence of chronic hepatitis B
[6]. In contrast, over 80% of the world’s population lives in
countries of intermediate (2%–7%) or high ($8%) prevalence [7];
although globally, hepatitis B (HB) vaccine programs have
expanded in recent years, most programs are too new to have
had an impact on the prevalence of chronic hepatitis B in
adolescents and adults.
The United States receives approximately 1 million immigrants
per year, mostly from countries of high or intermediate
prevalence. The Centers for Disease Control and Prevention
(CDC) recommends offering serologic screening for HBV infection
to all foreign-born residents from countries of intermediate to high
prevalence [4]. Serum hepatitis B surface antigen- (HBsAg)
screening is a reliable and relatively inexpensive means to detect
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hepatitis B virus infection. Chronically infected immigrants could
gain years of life if appropriate management is instituted before
symptoms occur [4]. However, the extent to which screening
recommendations for immigrants are followed is unknown.
The objectives of our analysis were to estimate the number of
chronic hepatitis B cases imported to the United States during
1974–2008, to determine major regions and countries of origin for
imported cases, to compare these numbers with the estimated
number of new U.S.-acquired chronic hepatitis B cases over that
time period, and to estimate mortality associated with imported
chronic hepatitis B cases.
Methods
We defined a case of imported chronic hepatitis B as pre-
existing chronic hepatitis B in a person immigrating to the United
States during 1974–2008. An immigrant was defined as any
person obtaining U.S. legal permanent residence during those
years. This definition excludes tourists, individuals on student or
work visas, and undocumented immigrants, but includes legal
immigrants who arrived from abroad after obtaining an
immigration visa, as well as visitors, refugees, or asylees already
in the United States who adjusted their legal residency status to
that of ‘‘permanent resident’’ (obtained a Green Card) [8]. These
applicants are required to undergo medical screening prior to
immigration or at the time of adjustment of status [9].
We defined a case of U.S.-acquired chronic hepatitis B as
chronic hepatitis B in an individual who was infected inside the
United States.
Data sources
Country-specific HBsAg prevalence rates were obtained from
CDC and WHO data (CDC expert solicitation circa 2003,
unpublished). Annual data on immigration by country and by age
category were obtained from Department of Homeland Security
(DHS) reports [10]. The number of new U.S.-acquired cases of
chronic hepatitis B was modeled from the number of cases of acute
hepatitis B reported to CDC through local and state health
departments from 1980 through 2008 [11]. The first step of this
model estimated the number of HBV infections each year by
dividing the reported number of cases in each age group by the
age-specific proportion of HBV infections that produce jaundice
(ranging from 5% in newborns to 30% in adults, based on data
from McMahon et al. [12]) and then multiplying by a constant to
account for under-reporting. The value of this constant (2.8) was
calibrated using an estimate of infections in persons less than 40
years old during the same period of time, obtained by means of
‘‘catalytic modeling’’ [13]. In the second step of the model, the
total number of infections in each age group in each year was
multiplied by an age-specific probability of progression to chronic
infection [3].
Data analysis
To estimate the number of cases imported to the United States
during 1974–2008, we multiplied country-specific HBsAg preva-
lence by the annual number of immigrants from each country. We
assumed that these prevalence rates remained constant over the
35-year time period. Results were aggregated by WHO region and
by 5-year time intervals. We estimated the projected mortality due
to late complications of chronic hepatitis B for cases acquired or
imported during 2004–2008, assuming that cases from low-
prevalence countries were likely infected during later childhood
(e.g. after age 5 years) or adulthood and therefore had a 15%
chance of related mortality, whereas cases from intermediate to
high prevalence countries were likely infected during infancy and
had a 25% chance of related mortality [4].
Ethics approval and human subjects consent were not required
for this analysis, because no individualized data were collected,
and no serologic testing was performed. Because human subjects
were not used, the CDC IRB did not specifically waive the need
for consent. The data are based on estimated HBsAg prevalence
rates and overall numbers of immigrants to the United States
during the stated period.
Results
During 1974–2008, 27.9 million people from 225 countries
and territories immigrated to the United States, with a general
upwards trend in immigration numbers (Figure 1). Of these,
63% were born in countries of intermediate or high chronic
HBV infection prevalence ($2%). Data on age at immigration
were available only for 2004–2008, during which the median
age category for immigrants was 30–34 years. The largest
number of immigrants came from the Americas Region (13
million) and the smallest number from the African Region
(940,000) (Table 1).
An estimated 1.3 million new cases of chronic HBV infection
were imported to the United States during 1974–2008. The
overall estimated prevalence of chronic HBV infection among all
new immigrants over that time period was 4.6%. The general
upward trend in estimated imported cases, from 105,750 cases in
1974–1978 to 268,800 cases in 2004–2008, reflects the upward
trend in immigration (Figure 2). In contrast to the U.S. HBsAg
prevalence of ,0.3%, the total estimated prevalence among all
immigrants to the U.S. during 2004–2008 was 4.9%.
The majority of estimated imported chronic hepatitis B cases
(724,000, or 55.2%) were from the Western Pacific Region; the
number of cases from the Western Pacific Region was 2.4–5.9
times greater than the second leading region for estimated cases
for each 5-year time period (Figure 2). Overall, the leading three
countries of birth for imported cases were the Philippines (176,520
estimated cases), China (164,640 cases), and Vietnam (144,100
cases). Together, these counties accounted for 37% of the
estimated total burden of imported chronic hepatitis B.
During 1974–1978 and 2004–2008, the number of imported
chronic hepatitis B cases from the African Region increased from
3,238 to 32,617. The African Region overtook the Americas
Region as the region of origin for the second largest number of
imported cases during 2004–2008, although the African Region
still had the smallest number of U.S. immigrants (6.3%) during
those years. The African country with the most U.S. immigrants
during 1974–1978 was South Africa (5,835 immigrants) with an
estimated HBsAg prevalence of 8%, whereas the top African
country for U.S. immigrants during 2004–2008 was Ethiopia
(60,720 immigrants and 11% prevalence).
The difference between the estimated incidences of new U.S.-
acquired and newly imported chronic HBV infections increased
over time. In 1988, there were roughly the same number of
estimated U.S.-acquired and newly imported infections (,30,000).
By 2006, the estimated number of U.S.-acquired infections had
declined to 3,700, while the estimated number of newly imported
infections had risen to 62,000—nearly 17 times the U.S.-acquired
number (Figure 3).
During 2004–2008, there was an average of 53,800 newly
imported cases of chronic HBV infection per year and 3,800 new
U.S.-acquired cases per year, for a total of 57,600 cases each year.
Of these, approximately 25%, or 14,000, will eventually develop
fatal complications as a result of the infection if appropriate clinical
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management is not implemented. Most of these deaths (95.8% or
13,110) would be in immigrants with imported chronic infection.
Discussion
Our data suggest that over the past 35 years in the United States
chronic HBV infection has become a disease affecting immigrants
disproportionately. This trend is the result of a substantial decline in
new HBV infections acquired in the United States in the past 20 years
compared to a lack of decline in the number of imported cases, such
that well over 90% of new cases of chronic hepatitis B in the United
States are now attributable to importation. Certain populations of
immigrants, such as those from the Western Pacific and Sub-Saharan
African regions, are likely at the highest risk of HBV infection prior to
immigration. The national strategy for elimination of domestic
transmission of HBV through immunization must take into account
the burden of disease among foreign-born Americans.
This U.S. hepatitis B immunization strategy, first recommended
by the Advisory Committee on Immunization Practices (ACIP) in
1991, calls for routine vaccination of infants against HBV infection
beginning at birth, catch-up vaccination for older children and
adolescents who have not completed the series, screening of all
pregnant women to reduce transmission to the newborn, and
vaccination of at-risk adults, including international travelers to
regions of high or intermediate prevalence [14]. Such measures
have led to a substantial decline in new U.S.-acquired cases, but
cannot prevent infections acquired prior to immigration.
However, early diagnosis of chronic HBV infection can benefit
immigrants and their families. Since 2008, CDC has recom-
mended serologic screening of persons born in countries with
either high or intermediate HBsAg seroprevalence [4], but
immigrants are likely inconsistently screened [15–16]. Recent
studies have demonstrated the cost-effectiveness of screening
migrant populations for chronic HBV infection, both in the U.S.
and in other countries [17–18], due to the potential for
intervention in the disease process at an earlier stage [19–20].
Household members of persons with chronic HBV infection
should be offered screening, and if susceptible, vaccination.
Voluntary screening in the United States after immigration
would involve significant education and outreach efforts, in order
to ensure that a large proportion of at-risk immigrants are tested.
All immigrant applicants to the United States undergo a federally
required medical exam as part of the application process; however,
its purpose is to identify inadmissible conditions, such as active
tuberculosis. Chronic HBV infection is not a condition that would
preclude immigration, and therefore is not screened for at that
time. The required exam may still provide an opportunity for
education of applicants from intermediate and high risk countries
about the disease and the importance of testing after arrival in the
United States.
Such education could occur in conjunction with vaccination.
Immigrants are required to receive ACIP-recommended vaccines
during the exam; therefore, immigrating children receive hepatitis
B vaccine [20]. However, there is no ACIP recommendation for
Figure 1. U.S. Immigration by WHO Region of Origin, 1974–2008.
doi:10.1371/journal.pone.0027717.g001
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Table 1. Number of Immigrants, Estimated HBsAg prevalence, and number of imported chronic hepatitis B cases by country of
birth, 1974–2008.
Birth country No. immigrants* (% ) Est HBsAg prevalence (%)** Chronic hepatitis B cases (%)
Region (no. countries)**
Africa (48) 939,183 (3.3) 11.1 104,698 (8.0)
Americas (49) 13,201,197 (46.7) 1.6 207,800 (15.8)
Eastern Mediterranean (24) 1,695,778 (6.0) 5.0 85,565 (6.5)
Europe (58) 3,994,078 (14.1) 2.9 117,335 (8.9)
Southeast Asia (9) 1,847,292 (6.5) 4.0 73,360 (5.6)
Western Pacific (38) 6,604,083 (23.4) 11.0 724,002 (55.2)
TOTAL 28,281,611 (100.0) 4.6 1,312,760 (100.0)
Top 10{
Philippines 1,765,203 (6.2) 10.0 176,520 (13.4)
China 1,372,025 (4.9) 12.0 164,643 (12.5)
Vietnam 1,200,863 (4.2) 12.0 144,103 (11.0)
Korea 918,505 (3.2) 12.0 110,221 (8.4)
Mexico 5,807,590 (20.5) 1.0 58,076 (4.4)
India 1,323,110 (4.7) 3.0 39,693 (3.0)
Taiwan 313,643 (1.1) 12.0 37,637 (2.9)
Dominican Republic 940,769 (3.3) 4.0 37,631 (2.8)
Haiti 532,968 (1.9) 5.0 26,648 (2.0)
Hong Kong 211,472 (0.75) 12.0 25,377 (1.9)
*From United States Department of Homeland Security, for persons obtaining legal permanent residency in United States (www.dhs.gov/files/statistics/publications/
yearbook.shtm).
**World Health Organization regions. Estimated HBsAg prevalence by region is the weighted average of estimated prevalence for each country in the region.
{Top 10 countries by estimated number of imported chronic hepatitis B cases.
doi:10.1371/journal.pone.0027717.t001
Figure 2. Estimated Cases of Imported Chronic HBV Infection by WHO Region of Origin, 1974–2008.
doi:10.1371/journal.pone.0027717.g002
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HBV screening prior to vaccination; this may impart a false sense
of immunity among vaccinated, HBV- infected individuals and
discourage families from seeking screening for their child after
immigration. Further, although hepatitis B vaccine is ACIP-
recommended for certain groups of at-risk adults, there is no
specific recommendation for vaccination of adult immigrants from
intermediate or high-endemicity countries. Vaccine stakeholders
should consider the current application of hepatitis B vaccine
guidelines in immigrating populations, and determine whether
more specific recommendations for vaccination of immigrants and
others from intermediate or high-risk countries are warranted,
including discussion of whether hepatitis B screening should be
recommended for such individuals prior to vaccination.
Global Hepatitis B (HB) vaccine programs are another critical
disease control measure that will eventually reduce chronic
hepatitis B importation into the United States, a country of
immigrants [21]. HB vaccine is highly effective in preventing
infection [22], and as of 2008, the primary 3-dose series for infants
and children has been introduced in 180 (92%) countries
worldwide [23]. However, vaccine coverage is not optimal in
many of these countries. For example, only a third of the countries
with a high prevalence of chronic HBV infection have imple-
mented the birth dose of HB vaccine [23]. While global
immunization programs are dramatically reducing HBV infection
rates in younger age groups, there would be a slower decline in the
rates of chronic hepatitis B among U.S. immigrants, whose
median age is currently 30–34 years [10], emphasizing the
importance of screening programs targeting immigrant groups.
Our data should be interpreted with some caution. The
prevalence estimates used are assumed constant for 1974–2008,
while in reality, country-specific prevalence data may be changing.
In addition, the data used are from a variety of sources and, in the
case of countries with limited epidemiologic data, represent expert
consensus rather than actual serologic prevalence. Another
limitation is that country prevalence estimates may not be fully
representative of the U.S. immigrant population, since immigrants
may be derived from certain ethnic groups or regions which may
have different HBV prevalence rates than the national average,
and we did not estimate the contribution from certain groups for
whom reliable population data do not exist, such as students on
temporary visas or undocumented immigrants, although the
estimated change in imported cases due to the 1989–1993 spike
in Pan-American immigrants from low HBsAg-prevalence coun-
tries when amnesty was granted to undocumented immigrants
[24]—still substantially dwarfed by cases imported from the
Western Pacific region (Figure 2)—may provide an estimate of the
effect from such groups. Nonetheless, even a cautious interpreta-
tion of these estimates would suggest that there is a dispropor-
tionate burden of disease in new Americans. Future studies could
determine the actual, rather than estimated, HBV seroprevalence
among new immigrants to the United States and assess the
implementation and impact of CDC screening recommendations
in reducing related morbidity and mortality among immigrants.
In conclusion, chronic hepatitis B is an important global public
health concern, which in the United States disproportionately and
increasingly affects the immigrant population. Because global and
national immunization programs would not assist many already-
infected current immigrants, earlier identification of infection is
needed to prompt the initiation of appropriate disease control
measures. Early screening would enable earlier referral for
monitoring and therapy in the United States, and promote patient
awareness and education. Such measures could reduce morbidity
and mortality, as well as transmission of a common but potentially
fatal infection, among new Americans.
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